Chung-Pu Wu
19PUBLICATIONS
7CO-AUTHORS
Get your video featured.
Publish with JoVEGet your video featured.
Publish with JoVE
Publications (19)
Sort by Publication Date:
|Mar 16, 2026
Befotertinib restored chemosensitivity to multidrug-resistant cancer cells by inhibiting the drug efflux activity of ABCB1.Yen-Ching Li, Megumi Murakami, Yang-Hui Huang
|May 25, 2024
ABCG2 Mediates Resistance to the Dual EGFR and PI3K Inhibitor MTX-211 in Cancer Cells.Chung-Pu Wu, Cheng-Yu Hung, Megumi Murakami
|Jan 17, 2024
Epidermal Growth Factor Receptor Inhibitor Mobocertinib Resensitizes Multidrug-Resistant Cancer Cells by Attenuating the Human ATP-Binding Cassette Subfamily B Member 1 and Subfamily G Member 2.Yen-Ching Li, Sung-Han Hsiao, Megumi Murakami
|Nov 25, 2023
Imperatorin Restores Chemosensitivity of Multidrug-Resistant Cancer Cells by Antagonizing ABCG2-Mediated Drug Transport.Chung-Pu Wu, Megumi Murakami, Yen-Ching Li
|Sep 28, 2023
Furmonertinib, a Third-Generation EGFR Tyrosine Kinase Inhibitor, Overcomes Multidrug Resistance through Inhibiting ABCB1 and ABCG2 in Cancer Cells.Chung-Pu Wu, Yen-Ching Li, Megumi Murakami
|Apr 13, 2023
ABCB1 and ABCG2 Overexpression Mediates Resistance to the Phosphatidylinositol 3-Kinase Inhibitor HS-173 in Cancer Cell Lines.Chung-Pu Wu, Cheng-Yu Hung, Ya-Ju Hsieh
Pageof 4
